Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CssBA
- Development stage
- Phase 2
- Lead developer
- PATH Vaccine Solutions
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Intradermal
01
Overview
CssBA is a recombinant protein vaccine candidate designed to prevent infection by enterotoxigenic Escherichia coli (ETEC), specifically targeting the CS6 colonization factor. It is a heterodimeric fusion protein composed of components derived from the ETEC CS6 subunits CssA and CssB. The vaccine elicits strong IgG and IgA anti-CS6 antibody responses in preclinical models and has been evaluated in Phase 1 clinical trials for safety and immunogenicity when administered intramuscularly or intradermally, with or without adjuvant (such as dmLT). The lead developer is PATH Vaccine Solutions.
- Other names
- CssBA
02
Targets
SulfatideCS6 (Colonization factor antigen 6)
Beyond the preview
Go deeper on CssBA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CssBA.